Does Rallies show 13F holders for TBPH?

Yes. Rallies tracks hedge fund and 13F ownership data for TBPH, including fund names, share counts, latest tracked quarter, and position changes when available.

Is TBPH research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TBPH. It does not provide personalized investment advice.

TBPH (Theravance Biopharma, Inc.) Stock Analysis - Hedge Fund Holdings

Theravance Biopharma, Inc. (TBPH) is a publicly traded Healthcare sector company. As of May 21, 2026, TBPH trades at $16.55 with a market cap of $838.25M and a P/E ratio of 7.31. TBPH moved +1.72% today. Year to date, TBPH is -10.15%; over the trailing twelve months it is +75.13%. Its 52-week range spans $7.88 to $21.03. Analyst consensus is buy with an average price target of $16.61. Rallies surfaces TBPH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns TBPH stock?

Hedge funds tracked by Rallies that own TBPH include Baupost Group. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Theravance Biopharma, Inc..

TBPH Key Metrics

Key financial metrics for TBPH
Metric	Value
Price	$16.55
Market Cap	$838.25M
P/E Ratio	7.31
EPS	$2.26
Dividend Yield	0.00%
52-Week High	$21.03
52-Week Low	$7.88
Volume	0
Avg Volume	0
Revenue (TTM)	$109.78M
Net Income	$114.54M
Gross Margin	0.00%

Top Hedge Funds Holding TBPH

Baupost Group holds 4.20M shares of TBPH, changed -36.31% as of Jun 30, 2024.

Latest TBPH News

Q1 Collaboration Revenue Rises 15% to $17.7M as Costs Drop 20% — May 7, 2026
Theravance Biopharma Posts $61m Q4 Profit, EPS Miss Triggers 60% Cost-Cut Plan — Mar 19, 2026
Theravance Biopharma Shares Fall 33.7%, RSI at 21.5 Signals Oversold — Mar 9, 2026
Theravance Biopharma Shares Drop 26% as Ampreloxetine Trial Fails, Cuts Jobs 50% — Mar 4, 2026
Theravance Halves Workforce, Shuts R&D to Save $70M After Trial Failure — Mar 4, 2026

Recent TBPH Insider Trades

Farnum Rhonda sold 7.77K (~$108.09K) on Mar 16, 2026.
Farnum Rhonda sold 15.53K (~$217.48K) on Mar 16, 2026.
Farnum Rhonda sold 7.77K (~$108.07K) on Mar 16, 2026.

TBPH Analyst Consensus

6 analysts cover TBPH: 0 strong buy, 3 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $16.61.

Common questions about TBPH

Who owns TBPH stock?: Hedge funds tracked by Rallies that own TBPH include Baupost Group. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Theravance Biopharma, Inc..
Does Rallies show 13F holders for TBPH?: Yes. Rallies tracks hedge fund and 13F ownership data for TBPH, including fund names, share counts, latest tracked quarter, and position changes when available.
Is TBPH research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TBPH. It does not provide personalized investment advice.